After bringing Ranbaxy into its fold last year, India’s top drug-maker by market value Sun Pharmaceutical Industries Ltd is now setting its sights to acquire local rival Intas Pharmaceuticals Ltd, and is in ‘early talks’ in what could be a Rs 15,000 crore ($2.3 billion) deal, multiple sources familiar with the development told DEALSTREETASIA.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
